Compare AANJANEYA LIFECARE with Divis Laboratories - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DR. DATSONS LABS vs DIVIS LABORATORIES - Comparison Results

DIVIS LABORATORIES 
   Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DR. DATSONS LABS DIVIS LABORATORIES DR. DATSONS LABS/
DIVIS LABORATORIES
 
P/E (TTM) x -10.9 53.7 - View Chart
P/BV x 0.2 14.4 1.1% View Chart
Dividend Yield % 0.0 0.4 -  

Financials

 DR. DATSONS LABS   DIVIS LABORATORIES
EQUITY SHARE DATA
    DR. DATSONS LABS
Mar-14
DIVIS LABORATORIES
Mar-19
DR. DATSONS LABS/
DIVIS LABORATORIES
5-Yr Chart
Click to enlarge
High Rs1261,639 7.7%   
Low Rs311,115 2.8%   
Sales per share (Unadj.) Rs133.0186.3 71.4%  
Earnings per share (Unadj.) Rs0.251.0 0.3%  
Cash flow per share (Unadj.) Rs6.657.3 11.5%  
Dividends per share (Unadj.) Rs016.00 0.0%  
Dividend yield (eoy) %01.2 0.0%  
Book value per share (Unadj.) Rs128.8261.8 49.2%  
Shares outstanding (eoy) m31.66265.47 11.9%   
Bonus/Rights/Conversions FCCB--  
Price / Sales ratio x0.67.4 8.0%   
Avg P/E ratio x516.127.0 1,909.7%  
P/CF ratio (eoy) x11.824.0 49.3%  
Price / Book Value ratio x0.65.3 11.5%  
Dividend payout %031.4 0.0%   
Avg Mkt Cap Rs m2,477365,592 0.7%   
No. of employees `000NA11.8 0.0%   
Total wages/salary Rs m565,423 1.0%   
Avg. sales/employee Rs ThNM4,175.1-  
Avg. wages/employee Rs ThNM457.7-  
Avg. net profit/employee Rs ThNM1,141.8-  
INCOME DATA
Net Sales Rs m4,21149,463 8.5%  
Other income Rs m791,556 5.1%   
Total revenues Rs m4,28951,019 8.4%   
Gross profit Rs m56918,718 3.0%  
Depreciation Rs m2041,689 12.1%   
Interest Rs m43035 1,229.1%   
Profit before tax Rs m1318,551 0.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m-20-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m65,023 0.1%   
Profit after tax Rs m513,527 0.0%  
Gross profit margin %13.537.8 35.7%  
Effective tax rate %48.027.1 177.4%   
Net profit margin %0.127.3 0.4%  
BALANCE SHEET DATA
Current assets Rs m6,85246,501 14.7%   
Current liabilities Rs m6,7118,468 79.3%   
Net working cap to sales %3.376.9 4.4%  
Current ratio x1.05.5 18.6%  
Inventory Days Days161131 123.0%  
Debtors Days Days31886 371.0%  
Net fixed assets Rs m3,67325,797 14.2%   
Share capital Rs m317531 59.6%   
"Free" reserves Rs m3,76168,962 5.5%   
Net worth Rs m4,07869,493 5.9%   
Long term debt Rs m1,6710-   
Total assets Rs m12,63380,383 15.7%  
Interest coverage x1.0531.0 0.2%   
Debt to equity ratio x0.40-  
Sales to assets ratio x0.30.6 54.2%   
Return on assets %3.416.9 20.4%  
Return on equity %0.119.5 0.6%  
Return on capital %7.726.7 28.7%  
Exports to sales %22.90-   
Imports to sales %14.324.6 58.0%   
Exports (fob) Rs m964NA-   
Imports (cif) Rs m60212,187 4.9%   
Fx inflow Rs m96441,238 2.3%   
Fx outflow Rs m60712,405 4.9%   
Net fx Rs m35728,833 1.2%   
CASH FLOW
From Operations Rs m1,3459,543 14.1%  
From Investments Rs m-2,256-6,854 32.9%  
From Financial Activity Rs m-1,200-2,459 48.8%  
Net Cashflow Rs m-2,111230 -919.3%  

Share Holding

Indian Promoters % 4.5 52.0 8.7%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.0 11.8 -  
FIIs % 1.4 19.0 7.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 94.1 17.2 547.1%  
Shareholders   20,807 31,796 65.4%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DR. DATSONS LABS With:   FULFORD INDIA  VENUS REMEDIES  CIPLA  WOCKHARDT  AUROBINDO PHARMA  

Compare DR. DATSONS LABS With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Share Markets Open Marginally Higher; ONGC and M&M Top Gainers(09:30 am)

Asian share markets are trading on a positive note today as investors anticipated the start of corporate earnings seasons.

Related Views on News

DIVIS LABORATORIES Announces Quarterly Results (3QFY21); Net Profit Up 27.9% (Quarterly Result Update)

Feb 10, 2021 | Updated on Feb 10, 2021

For the quarter ended December 2020, DIVIS LABORATORIES has posted a net profit of Rs 5 bn (up 27.9% YoY). Sales on the other hand came in at Rs 17 bn (up 19.1% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (1QFY21); Net Profit Up 84.1% (Quarterly Result Update)

Aug 10, 2020 | Updated on Aug 10, 2020

For the quarter ended June 2020, DIVIS LABORATORIES has posted a net profit of Rs 5 bn (up 84.1% YoY). Sales on the other hand came in at Rs 17 bn (up 50.0% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

Nazara Technologies IPO: Should You Apply? (IPO)

Mar 17, 2021

Should you bet on this gaming company backed by ace investor Rakesh Jhunjhunwala?

DIVIS LABORATORIES Announces Quarterly Results (4QFY20); Net Profit Up 35.4% (Quarterly Result Update)

Jun 8, 2020 | Updated on Jun 8, 2020

For the quarter ended March 2020, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (up 35.4% YoY). Sales on the other hand came in at Rs 14 bn (up 9.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (3QFY20); Net Profit Down 4.9% (Quarterly Result Update)

Feb 6, 2020 | Updated on Feb 6, 2020

For the quarter ended December 2019, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (down 4.9% YoY). Sales on the other hand came in at Rs 14 bn (up 3.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

More Views on News

Most Popular

My Recent Recommendation Will Profit from the Global Supply Chain Crisis(Profit Hunter)

Mar 31, 2021

A tiny chemical company, started in the Licence Raj era, is a great example of a new wealth creating opportunity.

My Stock Trading Strategy(Fast Profits Daily)

Mar 31, 2021

In this video I'll show you exactly how I go about picking stocks for trading.

4 Stocks to Make Your Portfolio Immune to the Second Covid Wave(Profit Hunter)

Apr 6, 2021

Rather than predicting the market, successful investing is more about preparing well and placing your bets accordingly.

If the Market Falls, I Will Do This...(Fast Profits Daily)

Apr 1, 2021

What should you do if the market falls? In this video, I'll tell you what I will do.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

DR. DATSONS LABS SHARE PRICE


May 21, 2015 (Close)

TRACK DR. DATSONS LABS

  • Track your investment in DR. DATSONS LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DR. DATSONS LABS

DR. DATSONS LABS 5-YR ANALYSIS

COMPARE DR. DATSONS LABS WITH

MARKET STATS